Keyword: Crestor

BMS and Pfizer’s Eliquis and J&J and Bayer’s Xarelto will lead the pack in 2024, followed by Amgen’s Repatha, Novartis’ Entresto and J&J's Uptravi.

Texas spanked AstraZeneca as a repeat offender in announcing a pair of off-label marketing settlements.

Crestor sales nosedived by 42% to $389 million in Q1, well below analyst estimates, but execs hope new cancer drugs can cushion the fall.

AstraZeneca slashed CEO Pascal Soriot’s total pay by 34% in 2017, but that cut wasn’t deep enough for one influential voice on corporate governance.

With cash flow under pressure, AstraZeneca could struggle to live up to CEO Pascal Soriot's commitment to pay a generous dividend "today, tomorrow, and thereafter."

The 10 CV drugs we’re profiling here represent the best-sellers by global 2016 sales, excluding those that faced generic competition throughout the year.

A decade in biopharma has a way of featuring megablockbuster patent losses—and we mean mega, with a total $915B in lifetime sales.